The American Journal of Managed Care

FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
The American Journal of Managed Care

FDA Approval of Subcutaneous Amivantamab Is Significant Step Forward in NSCLC: Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...
Healio

Cutaquig enables modified subcutaneous immunoglobulin infusion regimens

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Targeted Oncology

FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...